Ascendis Pharma and Teijin Limited Establish Strategic Collaboration in Japan

Ascendis Pharma A/S (Nasdaq: ASND) has recently revealed an exclusive license agreement with Teijin Limited to advance the development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP, specifically targeting endocrinology rare diseases in Japan.

Jan Mikkelsen, Ascendis Pharma's President and CEO, expressed satisfaction with the partnership, highlighting Teijin Pharma's expertise in obtaining regulatory approval and commercializing rare disease and endocrinology product candidates in Japan. Mikkelsen emphasized that the collaboration signifies a significant stride towards achieving a global presence for Ascendis Pharma's current Endocrinology Rare Disease portfolio, aiming to address unmet medical needs among Japanese patients.

Ascendis Pharma's innovative TransCon technology platform, praising the suite of product candidates as highly differentiated with best-in-class potential. Uchikawa anticipated that the partnership would greatly contribute to advancing Teijin Limited's healthcare business vision, especially in addressing issues faced by patients, families, and communities dealing with rare and intractable diseases.

According to the agreement's terms, Ascendis Pharma is set to receive an upfront payment of $70 million, coupled with potential development and regulatory milestones totaling up to $175 million, transfer pricing, and additional commercial milestones. Furthermore, Ascendis Pharma stands to gain royalties on net sales in Japan, ranging up to the mid-20s percent, with variations based on the specific product.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!